{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:11:39Z","timestamp":1744503099401,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T00:00:00Z","timestamp":1508716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T00:00:00Z","timestamp":1508716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000098","name":"NIH Clinical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["ICMx"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40635-017-0159-9","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T16:03:04Z","timestamp":1508774584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anthrax immune globulin improves hemodynamics and survival during B. anthracis toxin-induced shock in canines receiving titrated fluid and vasopressor support"],"prefix":"10.1186","volume":"5","author":[{"given":"Dante A.","family":"Suffredini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xizhong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharmvir","family":"Jaswal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth E.","family":"Remy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven B.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Fitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahtab","family":"Moayeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Leppla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Q.","family":"Eichacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,23]]},"reference":[{"key":"159_CR1","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1164\/rccm.201102-0209CI","volume":"184","author":"DA Sweeney","year":"2011","unstructured":"Sweeney DA, Hicks CW, Cui X, Li Y, Eichacker PQ (2011) Anthrax infection. Am J Respir Crit Care Med 184:1333\u20131341","journal-title":"Am J Respir Crit Care Med"},{"key":"159_CR2","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1128\/IAI.59.10.3472-3477.1991","volume":"59","author":"C Pezard","year":"1991","unstructured":"Pezard C, Berche P, Mock M (1991) Contribution of individual toxin components to virulence of Bacillus anthracis. Infect Immun 59:3472\u20133477","journal-title":"Infect Immun"},{"key":"159_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1086\/510856","volume":"195","author":"X Cui","year":"2007","unstructured":"Cui X, Li Y, Li X, Laird MW, Subramanian M, Moayeri M, Leppla SH, Fitz Y, Su J, Sherer K, Eichacker PQ (2007) Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J Infect Dis 195:572\u2013580","journal-title":"J Infect Dis"},{"key":"159_CR4","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1086\/657408","volume":"202","author":"DA Sweeney","year":"2010","unstructured":"Sweeney DA, Cui X, Solomon SB, Vitberg DA, Migone TS, Scher D, Danner RL, Natanson C, Subramanian GM, Eichacker PQ (2010) Anthrax lethal and edema toxins produce different patterns of cardiovascular and renal dysfunction and synergistically decrease survival in canines. J Infect Dis 202:1885\u20131896","journal-title":"J Infect Dis"},{"key":"159_CR5","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/S0002-9440(10)62496-0","volume":"166","author":"JM Warfel","year":"2005","unstructured":"Warfel JM, Steele AD, D\u2019Agnillo F (2005) Anthrax lethal toxin induces endothelial barrier dysfunction. Am J Pathol 166:1871\u20131881","journal-title":"Am J Pathol"},{"key":"159_CR6","doi-asserted-by":"publisher","first-page":"4670","DOI":"10.2741\/2416","volume":"12","author":"LE Watson","year":"2007","unstructured":"Watson LE, Mock J, Lal H, Lu G, Bourdeau RW, Tang WJ, Leppla SH, Dostal DE, Frankel AE (2007) Lethal and edema toxins of anthrax induce distinct hemodynamic dysfunction. Front Biosci 12:4670\u20134675","journal-title":"Front Biosci"},{"key":"159_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6404a1","volume":"64","author":"WA Bower","year":"2015","unstructured":"Bower WA, Hendricks K, Pillai S, Guarnizo J, Meaney-Delman D (2015) Clinical framework and medical countermeasure use during an anthrax mass-casualty incident. MMWR Recomm Rep 64:1\u201322","journal-title":"MMWR Recomm Rep"},{"key":"159_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/hs.2015.0032","volume":"13","author":"E Huang","year":"2015","unstructured":"Huang E, Pillai SK, Bower WA, Hendricks KA, Guarnizo JT, Hoyle JD, Gorman SE, Boyer AE, Quinn CP, Meaney-Delman D (2015) Antitoxin treatment of inhalation anthrax: a systematic review. Health Secur 13:365\u2013377","journal-title":"Health Secur"},{"key":"159_CR9","doi-asserted-by":"publisher","first-page":"5684","DOI":"10.1128\/AAC.00458-13","volume":"57","author":"N Mytle","year":"2013","unstructured":"Mytle N, Hopkins RJ, Malkevich NV, Basu S, Meister GT, Sanford DC, Comer JE, Van Zandt KE, Al-Ibrahim M, Kramer WG, Howard C, Daczkowski N, Chakrabarti AC, Ionin B, Nabors GS, Skiadopoulos MH (2013) Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob Agents Chemother 57:5684\u20135692","journal-title":"Antimicrob Agents Chemother"},{"key":"159_CR10","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/j.vaccine.2016.03.006","volume":"34","author":"RJ Hopkins","year":"2016","unstructured":"Hopkins RJ, Kalsi G, Montalvo-Lugo VM, Sharma M, Wu Y, Muse DD, Sheldon EA, Hampel FC, Lemiale L (2016) Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults. Vaccine 34:2096\u20132105","journal-title":"Vaccine"},{"key":"159_CR11","unstructured":"Fisher RW (2015) Summary basis for regulatory action\u2014Anthrasil. Available from: \n                    http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/UCM443728.pdf\n                    \n                  . Accessed 10 Jan 2017"},{"key":"159_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3201\/eid2301.160608","volume":"23","author":"X Cui","year":"2017","unstructured":"Cui X, Nolen LD, Sun J, Booth M, Donaldson L, Quinn CP, Boyer AE, Hendricks K, Shadomy S, Bothma P, Judd O, McConnell P, Bower WA, Eichacker PQ (2017) Analysis of anthrax immune globulin intravenous with antimicrobial treatment in injection drug users, Scotland, 2009-2010. Emerg Infect Dis 23:56\u201365","journal-title":"Emerg Infect Dis"},{"key":"159_CR13","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1086\/512372","volume":"44","author":"JJ Walsh","year":"2007","unstructured":"Walsh JJ, Pesik N, Quinn CP, Urdaneta V, Dykewicz CA, Boyer AE, Guarner J, Wilkins P, Norville KJ, Barr JR, Zaki SR, Patel JB, Reagan SP, Pirkle JL, Treadwell TA, Messonnier NR, Rotz LD, Meyer RF, Stephens DS (2007) A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis 44:968\u2013971","journal-title":"Clin Infect Dis"},{"key":"159_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3201\/eid2002.130021","volume":"20","author":"J Griffith","year":"2014","unstructured":"Griffith J, Blaney D, Shadomy S, Lehman M, Pesik N, Tostenson S, Delaney L, Tiller R, DeVries A, Gomez T, Sullivan M, Blackmore C, Stanek D, Lynfield R (2014) Investigation of inhalation anthrax case, United States. Emerg Infect Dis 20:280\u2013283","journal-title":"Emerg Infect Dis"},{"key":"159_CR15","first-page":"280","volume":"55","author":"Centers for Disease Control and Prevention","year":"2006","unstructured":"Centers for Disease Control and Prevention (2006) Inhalation anthrax associated with dried animal hides\u2014Pennsylvania and New York City, 2006. MMWR Morb Mortal Wkly Rep 55:280\u2013282","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"159_CR16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/infdis\/jir834","volume":"205","author":"AV Barochia","year":"2012","unstructured":"Barochia AV, Cui X, Sun J, Li Y, Solomon SB, Migone TS, Subramanian GM, Bolmer SD, Eichacker PQ (2012) Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines. J Infect Dis 205:818\u2013829","journal-title":"J Infect Dis"},{"key":"159_CR17","unstructured":"Package insert and patient information\u2014ANTHRASIL (2015). Available from: \n                    http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM439812.pdf\n                    \n                  . Accessed 10 Jan 2017"},{"key":"159_CR18","doi-asserted-by":"publisher","first-page":"H2487","DOI":"10.1152\/ajpheart.00589.2007","volume":"293","author":"PC Minneci","year":"2007","unstructured":"Minneci PC, Deans KJ, Hansen B, Parent C, Romines C, Gonzales DA, Ying SX, Munson P, Suffredini AF, Feng J, Solomon MA, Banks SM, Kern SJ, Danner RL, Eichacker PQ, Natanson C, Solomon SB (2007) A canine model of septic shock: balancing animal welfare and scientific relevance. Am J Physiol Heart Circ Physiol 293:H2487\u2013H2500","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"159_CR19","doi-asserted-by":"publisher","first-page":"e106393","DOI":"10.1371\/journal.pone.0106393","volume":"9","author":"S Kammanadiminti","year":"2014","unstructured":"Kammanadiminti S, Patnaikuni RK, Comer J, Meister G, Sinclair C, Kodihalli S (2014) Combination therapy with antibiotics and anthrax immune globulin intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax. PLoS One 9:e106393","journal-title":"PLoS One"},{"key":"159_CR20","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/nature09446","volume":"467","author":"A Guichard","year":"2010","unstructured":"Guichard A, McGillivray SM, Cruz-Moreno B, van Sorge NM, Nizet V, Bier E (2010) Anthrax toxins cooperatively inhibit endocytic recycling by the Rab11\/Sec15 exocyst. Nature 467:854\u2013858","journal-title":"Nature"},{"key":"159_CR21","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/toxins3101278","volume":"3","author":"JM Warfel","year":"2011","unstructured":"Warfel JM, D\u2019Agnillo F (2011) Anthrax lethal toxin-mediated disruption of endothelial VE-cadherin is attenuated by inhibition of the Rho-associated kinase pathway. Toxins (Basel) 3:1278\u20131293","journal-title":"Toxins (Basel)"},{"key":"159_CR22","doi-asserted-by":"publisher","first-page":"e62576","DOI":"10.1371\/journal.pone.0062576","volume":"8","author":"F D\u2019Agnillo","year":"2013","unstructured":"D\u2019Agnillo F, Williams MC, Moayeri M, Warfel JM (2013) Anthrax lethal toxin downregulates claudin-5 expression in human endothelial tight junctions. PLoS One 8:e62576","journal-title":"PLoS One"},{"key":"159_CR23","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3390\/toxins3091185","volume":"3","author":"CW Hicks","year":"2011","unstructured":"Hicks CW, Cui X, Sweeney DA, Li Y, Barochia A, Eichacker PQ (2011) The potential contributions of lethal and edema toxins to the pathogenesis of anthrax associated shock. Toxins (Basel) 3:1185\u20131202","journal-title":"Toxins (Basel)"},{"key":"159_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/1741-7015-11-217","volume":"11","author":"KE Remy","year":"2013","unstructured":"Remy KE, Qiu P, Li Y, Cui X, Eichacker PQ (2013) B. anthracis associated cardiovascular dysfunction and shock: the potential contribution of both non-toxin and toxin components. BMC Med 11:217","journal-title":"BMC Med"},{"key":"159_CR25","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/jcmm.12075","volume":"17","author":"KM Coggeshall","year":"2013","unstructured":"Coggeshall KM, Lupu F, Ballard J, Metcalf JP, James JA, Farris D, Kurosawa S (2013) The sepsis model: an emerging hypothesis for the lethality of inhalation anthrax. J Cell Mol Med 17:914\u2013920","journal-title":"J Cell Mol Med"},{"key":"159_CR26","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.2741\/3382","volume":"14","author":"HB Golden","year":"2009","unstructured":"Golden HB, Watson LE, Lal H, Verma SK, Foster DM, Kuo SR, Sharma A, Frankel A, Dostal DE (2009) Anthrax toxin: pathologic effects on the cardiovascular system. Front Biosci (Landmark Ed) 14:2335\u20132357","journal-title":"Front Biosci (Landmark Ed)"},{"key":"159_CR27","first-page":"4009","volume":"13","author":"DL Goldman","year":"2008","unstructured":"Goldman DL, Casadevall A (2008) Anthrax-associated shock. Front Biosci 13:4009\u20134014","journal-title":"Front Biosci"},{"key":"159_CR28","doi-asserted-by":"publisher","first-page":"H238","DOI":"10.1152\/ajpheart.00185.2013","volume":"305","author":"Y Li","year":"2013","unstructured":"Li Y, Cui X, Solomon SB, Remy K, Fitz Y, Eichacker PQ (2013) B. anthracis edema toxin increases cAMP levels and inhibits phenylephrine-stimulated contraction in a rat aortic ring model. Am J Physiol Heart Circ Physiol 305:H238\u2013H250","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"159_CR29","doi-asserted-by":"publisher","first-page":"H781","DOI":"10.1152\/ajpheart.00163.2016","volume":"311","author":"Y Li","year":"2016","unstructured":"Li Y, Cui X, Xu W, Ohanjanian L, Sampath-Kumar H, Suffredini D, Moayeri M, Leppla S, Fitz Y, Eichacker PQ (2016) Nitric oxide production contributes to Bacillus anthracis edema toxin-associated arterial hypotension and lethality: ex vivo and in vivo studies in the rat. Am J Physiol Heart Circ Physiol 311:H781\u2013H793","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"159_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nature12510","volume":"501","author":"S Liu","year":"2013","unstructured":"Liu S, Zhang Y, Moayeri M, Liu J, Crown D, Fattah RJ, Wein AN, Yu ZX, Finkel T, Leppla SH (2013) Key tissue targets responsible for anthrax-toxin-induced lethality. Nature 501:63\u201368","journal-title":"Nature"},{"key":"159_CR31","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.1371\/journal.pone.0000466","volume":"2","author":"LE Watson","year":"2007","unstructured":"Watson LE, Kuo SR, Katki K, Dang T, Park SK, Dostal DE, Tang WJ, Leppla SH, Frankel AE (2007) Anthrax toxins induce shock in rats by depressed cardiac ventricular function. PLoS One 2:e466","journal-title":"PLoS One"},{"key":"159_CR32","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.3390\/toxins7124891","volume":"7","author":"DA Suffredini","year":"2015","unstructured":"Suffredini DA, Sampath-Kumar H, Li Y, Ohanjanian L, Remy KE, Cui X, Eichacker PQ (2015) Does Bacillus anthracis lethal toxin directly depress myocardial function? A review of clinical cases and preclinical studies. Toxins (Basel) 7:5417\u20135434","journal-title":"Toxins (Basel)"},{"key":"159_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa0810603","volume":"361","author":"TS Migone","year":"2009","unstructured":"Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD (2009) Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 361:135\u2013144","journal-title":"N Engl J Med"},{"key":"159_CR34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/IDR.S47305","volume":"7","author":"CE Kummerfeldt","year":"2014","unstructured":"Kummerfeldt CE (2014) Raxibacumab: potential role in the treatment of inhalational anthrax. Infect Drug Resist 7:101\u2013109","journal-title":"Infect Drug Resist"},{"key":"159_CR35","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1128\/AAC.04606-14","volume":"59","author":"TS Migone","year":"2015","unstructured":"Migone TS, Bolmer S, Zhong J, Corey A, Vasconcelos D, Buccellato M, Meister G (2015) Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax. Antimicrob Agents Chemother 59:1145\u20131151","journal-title":"Antimicrob Agents Chemother"},{"key":"159_CR36","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3389\/fmicb.2015.01320","volume":"6","author":"CW Tsai","year":"2015","unstructured":"Tsai CW, Morris S (2015) Approval of Raxibacumab for the treatment of inhalation anthrax under the US Food and Drug Administration \u201cAnimal Rule\u201d. Front Microbiol 6:1320","journal-title":"Front Microbiol"},{"key":"159_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40635-015-0043-4","volume":"3","author":"KE Remy","year":"2015","unstructured":"Remy KE, Cui X, Li Y, Sun J, Solomon SB, Fitz Y, Barochia AV, Al-Hamad M, Moayeri M, Leppla SH, Eichacker PQ (2015) Raxibacumab augments hemodynamic support and improves outcomes during shock with B. anthracis edema toxin alone or together with lethal toxin in canines. Intensive Care Med Exp 3:9","journal-title":"Intensive Care Med Exp"},{"key":"159_CR38","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/ilar.46.3.258","volume":"46","author":"NS Lipman","year":"2005","unstructured":"Lipman NS, Jackson LR, Trudel LJ (2005) Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications and information resources. ILAR J 46:258\u2013268","journal-title":"ILAR J"},{"key":"159_CR39","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1128\/AAC.04593-14","volume":"59","author":"B Biron","year":"2015","unstructured":"Biron B, Beck K, Dyer D, Mattix M, Twenhafel N, Nalca A (2015) Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax. Antimicrob Agents Chemother 59:2206\u20132214","journal-title":"Antimicrob Agents Chemother"},{"key":"159_CR40","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40265-016-0577-0","volume":"76","author":"SL Greig","year":"2016","unstructured":"Greig SL (2016) Obiltoxaximab: first global approval. Drugs 76:823\u2013830","journal-title":"Drugs"},{"key":"159_CR41","doi-asserted-by":"publisher","first-page":"5796","DOI":"10.1128\/AAC.01102-16","volume":"60","author":"BJ Yamamoto","year":"2016","unstructured":"Yamamoto BJ, Shadiack AM, Carpenter S, Sanford D, Henning LN, Gonzales N, O\u2019Connor E, Casey LS, Serbina NV (2016) Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre- and postexposure prophylaxis in animal models of inhalational anthrax. Antimicrob Agents Chemother 60:5796\u20135805","journal-title":"Antimicrob Agents Chemother"},{"key":"159_CR42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jim.2014.05.008","volume":"408","author":"RA Stoddard","year":"2014","unstructured":"Stoddard RA, Quinn CP, Schiffer JM, Boyer AE, Goldstein J, Bagarozzi DA, Soroka SD, Dauphin LA, Hoffmaster AR (2014) Detection of anthrax protective antigen (PA) using europium labeled anti-PA monoclonal antibody and time-resolved fluorescence. J Immunol Methods 408:78\u201388","journal-title":"J Immunol Methods"}],"container-title":["Intensive Care Medicine Experimental"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-017-0159-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40635-017-0159-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-017-0159-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T22:44:56Z","timestamp":1589669096000},"score":1,"resource":{"primary":{"URL":"https:\/\/icm-experimental.springeropen.com\/articles\/10.1186\/s40635-017-0159-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,23]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["159"],"URL":"https:\/\/doi.org\/10.1186\/s40635-017-0159-9","relation":{},"ISSN":["2197-425X"],"issn-type":[{"type":"electronic","value":"2197-425X"}],"subject":[],"published":{"date-parts":[[2017,10,23]]},"assertion":[{"value":"12 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The National Institutes of Health Clinical Center Animal Care and Use Committee approved this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"48"}}